RA Capital Management executed the largest insider purchase in Hemab Therapeutics' history, buying 2.54 million shares at $18.00, signaling strong conviction in the company's pipeline. This move is notable given the stock is currently trading 31.58% below its 52-week high of $36.61.
Price context
COAG is currently trading at $25.05, representing a 31.58% pullback from its 52-week high of $36.61, though it remains 6.62% above the 52-week low of $23.495.
Catalysts to watch
The recent IPO debut on May 3, 2026, priced at $34.00, and the company's reported 88.9% year-to-date return provide a strong entry point context for the insider buy. Additionally, the transaction represents the largest insider purchase in Hemab Therapeutics' history, signaling institutional confidence.
Risks
The recent IPO debut article explicitly notes 'Pipeline Risks' as a focus area for investors. Additionally, the industry's 90-day buying percentage is only 0.53%, indicating a lack of broader sector support for the stock.
AI-generated context from public data. Not investment advice. Verify before trading.